Navigation Links
Experimental Drug Offers Hope for Cystic Fibrosis Patients
Date:4/27/2010

Ataluren being tested in humans with several diseases caused by genetic mutations

TUESDAY, April 27 (HealthDay News) -- An experimental oral drug called ataluren may treat cystic fibrosis and other diseases caused by genetic "nonsense mutations," U.S. researchers report.

Nonsense mutations disrupt the way cells make proteins. About one-third of gene defects linked to human disease are believed to come from nonsense mutations, and ataluren holds promise for treating more than 2,400 such disorders, the study authors noted.

In cystic fibrosis, the lack of a certain protein results in an imbalance of salt and water in the linings of the lungs and other membranes. In this new study, researchers found that ataluren allowed the protein to be made in mouse cells where it was previously absent, which helped restore normal salt and water balance.

"When you treat a genetic disease, the bottom line is how much of the missing protein do you need to restore to have a therapeutic benefit," researcher David Bedwell, a professor in the microbiology department at the University of Alabama at Birmingham, said in a university news release.

"It comes down to the threshold of protein rescue. For some diseases, it might be 1 percent of protein you need restored, and for other diseases you may need 50 percent of protein restored," he explained.

Bedwell found that ataluren can restore up to 29 percent of normal protein function in mice with cystic fibrosis. The research, funded by PTC Therapeutics Inc., was presented April 26 at the Experimental Biology 2010 conference in Anaheim, Calif.

Ataluren is now being tested in humans with cystic fibrosis, hemophilia A, hemophilia B, Duchenne/Becker muscular dystrophy and other conditions.

More information

The Cystic Fibrosis Foundation has more about cystic fibrosis.



-- Robert Preidt



SOURCE: University of Alabama at Birmingham, news release, April 26, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Experimental stem cell treatment arrests acute lung injury in mice, study shows
2. RetiringbyDesign.com Offers Retirees a Smarter Way to Explore Living Options
3. Ovarian cancer study offers vital clues for new therapies
4. American Laser Centers Offers a Solution for Customers Whose Laser Cosmetic Providers Have Gone Out of Business
5. TotalTrans4m Offers Natural Product Just in Time for Wedding Season That Can Jump Start Weight Loss
6. Newly Relaunched Autoinsurance.net Offers Consumers Smart Tips To Consider When Purchasing Car Insurance
7. S.A. Lifeline Foundation Offers New and Improved Website for Those with Pornography Addictions
8. Arsa Offers High Quality Supplements, Cosmetics and Magic Scents from Mexico for Less Than $10
9. Study Offers Insights Into Male Pattern Baldness
10. SEO-Peace.com Extends The March Special SEO Special Offers And Revise Many Services
11. UNC study offers first clinical evidence of anti-cancer drug triggering viral infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), ... software tool, and the Cancer Patient Education Network (CPEN), an independent professional organization ... a new strategic alliance. , As CPEN’s strategic partner, HLI will help ...
(Date:10/12/2017)... ... October 12, 2017 , ... Farm Forward ... Berkeley, and other leading institutions in announcing the launch of the Leadership ... the way animals are raised for food. , Founding members of the Leadership ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... 2017   Divoti USA will engrave and ... standard of the latest FDA requirements, which stipulates new criteria regarding ... in need of Medical ID jewelry such as Medical ID Bracelets, ... engraved in terms of the new FDA requirements . ... Divoti offers this dark mark fiber ...
(Date:10/11/2017)... Oct. 11, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... facility in Las Piedras, Puerto Rico ... blades. Following ... facility sustained minor structural damage, temporary loss of power ... have been completed, manufacturing operations have resumed, and the ...
(Date:10/4/2017)... South Korea , Oct. 4, 2017  South ... its next-generation CPR training aide "cprCUBE" on Kickstarter. The ... chest compression during cardiac arrests with better efficiency compared ... It also offers real-time feedback on efficacy of the ... The crowdfunding campaign has a goal to raise $5,000. ...
Breaking Medicine Technology: